Arca
Skip to content
Tools
Tools

P2RX3: P2X purinoceptor 3

Extracellular ATP-activated non-selective cation channel.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on P2RX3, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved1

  • Gefapixant

Phase 31

  • Camlipixant

Phase 20

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      GefapixantApprovedAfferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Small moleculeAntagonistP2X purinoceptor 3 antagonist1
      CamlipixantPhase 3GSKSmall moleculeAntagonistP2X purinoceptor 3 antagonist1

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 2 in all, from ClinicalTrials.gov.
      A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)CamlipixantPhase 2RecruitingGlaxoSmithKlineApr 9, 2026
      The Real-world Treatment Satisfaction by Gefapixiant in RCCGefapixantNot applicableRecruitingNagoya City UniversityAug 7, 2024

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Aging0.32
      • Stress urinary incontinence0.26
      • Deep vein thrombosis0.20
      • Cardiac arrhythmia0.09
      • Gastroesophageal reflux disease0.08
      • Chronic interstitial cystitis0.08

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2998, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P56373, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.